Ask AI
ProCE Banner Activity

ACTG A5391/DO-IT Trial: Switching to DOR ± TDF vs Continuing INSTI + TAF/FTC in People With Obesity and HIV Infection

Conference Coverage
Slideset

In the ACTG A5391/DO-IT study of people with obesity and HIV infection who were receiving a stable INSTI + TAF/FTC regimen, switching the INSTI to doravirine with or without a simultaneous switch of TAF to TDF did not result in significant weight loss at 48 weeks vs continuing an INSTI + TAF/FTC regimen.

Released: July 15, 2025

Expiration: January 14, 2026

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

Partners

IAS

ProCE Banner